Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-3

Loving the extra details emerging here about the psychedelic clinics business model and collaboration.

"Clarion Clinics Group, the collaboration between Australia’s foremost clinical experts and IHL (84.5% owned
by IHL subsidiary Psychennex Pty Ltd), will provide treatment under the TGA regulated authorised prescriber
scheme, for the use of psilocybin for treatment-resistant depression (TRD) and the use of MDMA for PostTraumatic Stress Disorder (PTSD). A number of other depression and anxiety related disorders will be
treated with ketamine-assisted psychotherapy."

Also, others may already have known this, but it is news to me that they project the Australian market alone to grow to 2Bn in just 3 years for psychedelic-assisted psychotherapy. Since our clinics aim to offer all TGA approved therapies and we're getting in at ground zero, we really can aim to capture a decent portion of that market.

Exciting times. I haven't learned this news much from a 4c before and I'm only on the first page. Going to read on.